Amicus Therapeutics (FOLD) Up 6.4% Since Last Earnings Report: Can It Continue?

Core Insights - Amicus Therapeutics reported a strong Q3 2025 earnings performance, with adjusted earnings of 17 cents per share, surpassing the Zacks Consensus Estimate of 12 cents and up from 10 cents in the same quarter last year [3][4] - Revenues for Q3 2025 reached $169.1 million, reflecting a 19% year-over-year increase, and also exceeding the Zacks Consensus Estimate of $165 million [3][4] - The company maintained its 2025 financial guidance, expecting total revenue growth of 15-22% at constant exchange rates (CER) and projecting Galafold revenues to grow by 10-15% at CER [7][8] Financial Performance - Galafold sales amounted to $138.3 million, a 12% increase year-over-year at CER, although it fell short of the Zacks Consensus Estimate of $150 million [5] - Sales from Pombiliti + Opfolda reached $30.7 million, exceeding both the Zacks Consensus Estimate of $29.7 million and the internal model estimate of $29.4 million [5] - Adjusted operating expenses rose by 15% to $95.4 million in Q3 2025, while cash and marketable securities increased to $263.8 million from $231 million as of June 30, 2025 [6] Future Outlook - The company anticipates achieving positive GAAP net income in the second half of 2025 and aims to exceed $1 billion in total sales by 2028 [8] - Despite a recent downward trend in estimates, Amicus Therapeutics holds a Zacks Rank 1 (Strong Buy), indicating expectations for above-average returns in the coming months [11] - The overall VGM Score for Amicus is D, reflecting challenges in the value strategy, while growth and momentum scores are both C [10] Industry Context - Amicus Therapeutics operates within the Zacks Medical - Biomedical and Genetics industry, where competitor GSK reported revenues of $11.52 billion for the last quarter, marking a year-over-year increase of 10.6% [12] - GSK's earnings per share for the same period were $1.48, up from $1.27 a year ago, with a Zacks Rank 3 (Hold) [12][13]